Global Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) Therapeutics Pipeline Review 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Pipeline Review, H2 2016" drug pipelines to their offering.

This report provides comprehensive information on the therapeutic development for Tyrosine Protein Kinase JAK3, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tyrosine Protein Kinase JAK3 and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Tyrosine Protein Kinase JAK3 Overview
  3. Therapeutics Development
  4. Pipeline Products for Tyrosine Protein Kinase JAK3 - Overview
  5. Pipeline Products for Tyrosine Protein Kinase JAK3 - Comparative Analysis
  6. Tyrosine Protein Kinase JAK3 - Therapeutics under Development by Companies
  7. Tyrosine Protein Kinase JAK3 - Therapeutics under Investigation by Universities/Institutes
  8. Tyrosine Protein Kinase JAK3 Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Tyrosine Protein Kinase JAK3 - Products under Development by Companies
  13. Tyrosine Protein Kinase JAK3 - Products under Investigation by Universities/Institutes
  14. Tyrosine Protein Kinase JAK3 - Companies Involved in Therapeutics Development
  • Aclaris Therapeutics, Inc.
  • Advinus Therapeutics Ltd
  • Arrien Pharmaceuticals, LLC
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb Company
  • Chipscreen Biosciences Ltd
  • Creabilis SA
  • F. Hoffmann-La Roche Ltd.
  • Ligand Pharmaceuticals, Inc.
  • MYOS RENS Technology Inc.
  • Pfizer

For more information about this drug pipelines visit http://www.researchandmarkets.com/research/4t6m2k/tyrosine_protein

Related Topics: Enzymes

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716